Editorial comment: I can't help thinking that it makes more sense to let AI "explore strange new worlds and civilizations". In my words: "To go where no man should go".
- Most systems largely recover within weeks to ~12 months, but several do not fully return to baseline:weight-bearing bone (tibia, hip, spine), some retinal/ocular structural changes (globe flattening, choroidal folds, hyperopic shifts), brain ventricular enlargement, and molecular markers of accelerated aging (short telomeres, persistent gene-expression and chromosomal-inversion changes) can persist for years. No astronaut has suffered permanent vision loss or a clearly attributable radiation cancer, but lifetime risk is elevated and uncertain.
- The most durable deficits are skeletal: astronauts lose ~1–1.5% of bone mineral density per month, and after long (>6-month) missions only about a third recover preflight hip BMD and under half recover spine BMD at one year; lost trabecular microstructure ("struts") appears permanently gone even when density partially rebounds.
- The biggest unknowns are deep-space-specific: ISS crews are shielded by Earth's magnetosphere, so radiation, kidney damage, and combined microgravity-plus-radiation effects on a multi-year Mars mission remain extrapolations from animal/analog data and the single n=1 year-long Twins Study rather than from direct human evidence.
- Most systems largely recover within weeks to ~12 months, but several do not fully return to baseline:weight-bearing bone (tibia, hip, spine), some retinal/ocular structural changes (globe flattening, choroidal folds, hyperopic shifts), brain ventricular enlargement, and molecular markers of accelerated aging (short telomeres, persistent gene-expression and chromosomal-inversion changes) can persist for years. No astronaut has suffered permanent vision loss or a clearly attributable radiation cancer, but lifetime risk is elevated and uncertain.
- The most durable deficits are skeletal: astronauts lose ~1–1.5% of bone mineral density per month, and after long (>6-month) missions only about a third recover preflight hip BMD and under half recover spine BMD at one year; lost trabecular microstructure ("struts") appears permanently gone even when density partially rebounds.
- The biggest unknowns are deep-space-specific: ISS crews are shielded by Earth's magnetosphere, so radiation, kidney damage, and combined microgravity-plus-radiation effects on a multi-year Mars mission remain extrapolations from animal/analog data and the single n=1 year-long Twins Study rather than from direct human evidence.
Key Findings
Bone is the signature long-term casualty. Loss runs ~1–1.5%/month (roughly 10× the osteoporotic rate), concentrated in weight-bearing sites. In a 17-astronaut HR-pQCT study (Gabel et al., Scientific Reports 2022), tibia strength and density remained 0.9–2.1% below preflight a full year after return, and 9 of 17 never recovered tibia BMD. An LSAH cohort found only 34% of astronauts regained preflight hip BMD and 46.8% spine BMD at one year. Lost trabecular struts cannot be rebuilt—only remaining ones thicken.
Muscle atrophies fast but recovers better than bone. Calf muscle volume drops ~13% over 6 months (soleus ~15%, gastrocnemius ~10%), with ~30% loss of peak power, despite ~2.5 hours/day of exercise. Antigravity slow-twitch (type I) fibers are hit hardest. Most muscle mass returns within months to ~1 year, though full functional/fiber-type recovery can lag.
Cardiovascular deconditioning is real but largely reversible. The heart atrophies (~8–10% mass loss in some studies), becomes 9.4% more spherical (sphericity index falling from 2.01 to 1.82, p=0.0008, in a 12-astronaut NASA study), and VO2max/aerobic capacity falls (peak declines of 11–28% on landing day). Orthostatic intolerance affects a large fraction of returning long-duration crew. Plasma volume drops ~10–17%. These mostly resolve within days to weeks with reconditioning and fluid loading.
SANS (Spaceflight-Associated Neuro-Ocular Syndrome) is the most worrying partly-irreversible finding.Driven by headward fluid shifts, it produces optic disc edema, globe flattening, choroidal folds, and hyperopic shifts in roughly 60–70% of long-duration crew. Disc edema usually resolves in weeks–months, but globe flattening, choroidal folds, and refractive shifts can persist for years. No permanent vision loss has been reported, but it's considered a possible warning sign.
The brain physically remodels. Ventricles (CSF cavities) enlarge ~11–25% after long missions, the brain shifts upward, and recovery is only partial at 6–12 months. Crews need roughly 3 years between missions for ventricles to recover compensatory capacity.
Radiation is the dominant deep-space risk. A 6-month ISS mission delivers on the order of 72–160 mSv depending on the solar cycle; Scott Kelly's ~340-day mission gave an effective dose of 146.34 mSv. NASA's career limit has been standardized to 600 mSv (3% excess cancer death risk). A Mars round trip would exceed these limits.
Immune dysregulation and latent virus reactivation persist throughout flight. Latent herpesviruses (EBV, VZV, CMV) reactivate in a majority of long-duration crew, and aspects of adaptive immunity stay suppressed. Up to half of returning astronauts show some immunodeficiency.
The microbiome shifts but recovers. Gut, skin, and nasal microbial communities change in flight and converge between crewmates, but largely return to baseline within days to weeks of landing.
The Twins Study showed most molecular changes reverse. ~93% of Scott Kelly's altered gene expression returned to normal within 6 months; ~7% remained disrupted (immune, DNA repair, bone formation). Telomeres unexpectedly lengthened in flight then shortened rapidly on return, leaving more critically short telomeres than before—a possible accelerated-aging signature.
Bone is the signature long-term casualty. Loss runs ~1–1.5%/month (roughly 10× the osteoporotic rate), concentrated in weight-bearing sites. In a 17-astronaut HR-pQCT study (Gabel et al., Scientific Reports 2022), tibia strength and density remained 0.9–2.1% below preflight a full year after return, and 9 of 17 never recovered tibia BMD. An LSAH cohort found only 34% of astronauts regained preflight hip BMD and 46.8% spine BMD at one year. Lost trabecular struts cannot be rebuilt—only remaining ones thicken.
Muscle atrophies fast but recovers better than bone. Calf muscle volume drops ~13% over 6 months (soleus ~15%, gastrocnemius ~10%), with ~30% loss of peak power, despite ~2.5 hours/day of exercise. Antigravity slow-twitch (type I) fibers are hit hardest. Most muscle mass returns within months to ~1 year, though full functional/fiber-type recovery can lag.
Cardiovascular deconditioning is real but largely reversible. The heart atrophies (~8–10% mass loss in some studies), becomes 9.4% more spherical (sphericity index falling from 2.01 to 1.82, p=0.0008, in a 12-astronaut NASA study), and VO2max/aerobic capacity falls (peak declines of 11–28% on landing day). Orthostatic intolerance affects a large fraction of returning long-duration crew. Plasma volume drops ~10–17%. These mostly resolve within days to weeks with reconditioning and fluid loading.
SANS (Spaceflight-Associated Neuro-Ocular Syndrome) is the most worrying partly-irreversible finding.Driven by headward fluid shifts, it produces optic disc edema, globe flattening, choroidal folds, and hyperopic shifts in roughly 60–70% of long-duration crew. Disc edema usually resolves in weeks–months, but globe flattening, choroidal folds, and refractive shifts can persist for years. No permanent vision loss has been reported, but it's considered a possible warning sign.
The brain physically remodels. Ventricles (CSF cavities) enlarge ~11–25% after long missions, the brain shifts upward, and recovery is only partial at 6–12 months. Crews need roughly 3 years between missions for ventricles to recover compensatory capacity.
Radiation is the dominant deep-space risk. A 6-month ISS mission delivers on the order of 72–160 mSv depending on the solar cycle; Scott Kelly's ~340-day mission gave an effective dose of 146.34 mSv. NASA's career limit has been standardized to 600 mSv (3% excess cancer death risk). A Mars round trip would exceed these limits.
Immune dysregulation and latent virus reactivation persist throughout flight. Latent herpesviruses (EBV, VZV, CMV) reactivate in a majority of long-duration crew, and aspects of adaptive immunity stay suppressed. Up to half of returning astronauts show some immunodeficiency.
The microbiome shifts but recovers. Gut, skin, and nasal microbial communities change in flight and converge between crewmates, but largely return to baseline within days to weeks of landing.
The Twins Study showed most molecular changes reverse. ~93% of Scott Kelly's altered gene expression returned to normal within 6 months; ~7% remained disrupted (immune, DNA repair, bone formation). Telomeres unexpectedly lengthened in flight then shortened rapidly on return, leaving more critically short telomeres than before—a possible accelerated-aging signature.
Details
Cardiovascular system
In microgravity, ~2 liters of fluid shift headward, the heart no longer pumps against gravity, and rapid deconditioning follows. Studies have documented cardiac atrophy of roughly 8–10% and a ~10% reduction in left ventricular mass after as little as 10 days, plus a 17% reduction in plasma volume in the first weeks. James Thomas and colleagues, presenting a 12-astronaut study at the American College of Cardiology's 63rd Annual Scientific Session (2014), found the heart became 9.4% more spherical in microgravity—the sphericity index falling from 2.01 preflight to 1.82 in orbit (p=0.0008)—a shape change that could predispose to dysfunction. Aerobic capacity (VO2max) declines; astronauts can lose up to ~25% of aerobic capacity on long missions, with peak VO2 declines of 11–28% (mean ~18%) measured on landing day, recovering to baseline by about two weeks post-flight (R+14).
Orthostatic intolerance—the inability to maintain blood pressure on standing—has historically been one of the signature post-landing problems. NASA's Human Research Program Evidence Report states it affects about 20–30% of crew on short-duration (4–18 day) missions and 83% of those on long-duration missions, with tilt-test data showing only 2 of 6 ISS astronauts able to complete the test on landing day versus 52 of 65 Shuttle astronauts. However, a 2026 systematic review/meta-analysis in Acta Astronautica of 221 astronauts found pooled orthostatic-intolerance incidence of 30% (95% CI, 24–38%) and, "contrary to expectations," found mission duration was not associated with incidence. The mechanism combines hypovolemia, cardiac atrophy, reduced stroke volume, and blunted norepinephrine/vascular responses. Modern countermeasures (in-flight exercise, fluid loading, compression garments) mean most astronauts can now stand within hours of landing. QT-interval prolongation and arrhythmias have been reported in long—but not short—duration flight. Cardiovascular deconditioning is largely reversible with reconditioning.
In microgravity, ~2 liters of fluid shift headward, the heart no longer pumps against gravity, and rapid deconditioning follows. Studies have documented cardiac atrophy of roughly 8–10% and a ~10% reduction in left ventricular mass after as little as 10 days, plus a 17% reduction in plasma volume in the first weeks. James Thomas and colleagues, presenting a 12-astronaut study at the American College of Cardiology's 63rd Annual Scientific Session (2014), found the heart became 9.4% more spherical in microgravity—the sphericity index falling from 2.01 preflight to 1.82 in orbit (p=0.0008)—a shape change that could predispose to dysfunction. Aerobic capacity (VO2max) declines; astronauts can lose up to ~25% of aerobic capacity on long missions, with peak VO2 declines of 11–28% (mean ~18%) measured on landing day, recovering to baseline by about two weeks post-flight (R+14).
Orthostatic intolerance—the inability to maintain blood pressure on standing—has historically been one of the signature post-landing problems. NASA's Human Research Program Evidence Report states it affects about 20–30% of crew on short-duration (4–18 day) missions and 83% of those on long-duration missions, with tilt-test data showing only 2 of 6 ISS astronauts able to complete the test on landing day versus 52 of 65 Shuttle astronauts. However, a 2026 systematic review/meta-analysis in Acta Astronautica of 221 astronauts found pooled orthostatic-intolerance incidence of 30% (95% CI, 24–38%) and, "contrary to expectations," found mission duration was not associated with incidence. The mechanism combines hypovolemia, cardiac atrophy, reduced stroke volume, and blunted norepinephrine/vascular responses. Modern countermeasures (in-flight exercise, fluid loading, compression garments) mean most astronauts can now stand within hours of landing. QT-interval prolongation and arrhythmias have been reported in long—but not short—duration flight. Cardiovascular deconditioning is largely reversible with reconditioning.
Musculoskeletal system
Bone. This is the most consistently documented incompletely-reversible effect. Bone loss runs ~1–1.5%/month at the proximal femur, roughly 10× the rate of terrestrial osteoporosis. Gabel et al. (Scientific Reports 2022, n=17, 4–7 month missions) found that 12 months after return, median tibia bone strength and BMD remained 0.9–2.1% below preflight; astronauts on longer (>6-month) missions had a –3.9% strength deficit vs –0.4% for shorter missions, and 9 of 17 never recovered tibia BMD. The LSAH retrospective cohort found that at 1 year postflight only 34.0% of astronauts achieved preflight hip BMD and 46.8% achieved preflight spine BMD, with >6-month crews recovering slower at spine, hip, and femur—though no increased 10-year fracture risk was detected. Structurally, lost trabecular struts disconnect and cannot be rebuilt; recovery thickens surviving struts onto a permanently altered scaffold. Countermeasures: the bisphosphonate alendronate combined with the Advanced Resistive Exercise Device (ARED) suppresses resorption and largely prevents the loss; exercise alone partially offsets it but does not prevent trabecular loss.
Muscle. Trappe et al. (J Appl Physiol 2009, 6-month ISS, n=9) found calf volume dropped 13±2% (soleus –15%, gastrocnemius –10%), peak power fell ~32%, with a shift from slow to fast myosin fiber type. Lumbar paraspinal muscles atrophy 4.6–8.4% but generally recover within a year. Muscle recovers substantially faster than bone—mass mostly returns within months to a year—but full fiber-type and functional recovery can lag, and individual factors (age, sex) matter.
Bone. This is the most consistently documented incompletely-reversible effect. Bone loss runs ~1–1.5%/month at the proximal femur, roughly 10× the rate of terrestrial osteoporosis. Gabel et al. (Scientific Reports 2022, n=17, 4–7 month missions) found that 12 months after return, median tibia bone strength and BMD remained 0.9–2.1% below preflight; astronauts on longer (>6-month) missions had a –3.9% strength deficit vs –0.4% for shorter missions, and 9 of 17 never recovered tibia BMD. The LSAH retrospective cohort found that at 1 year postflight only 34.0% of astronauts achieved preflight hip BMD and 46.8% achieved preflight spine BMD, with >6-month crews recovering slower at spine, hip, and femur—though no increased 10-year fracture risk was detected. Structurally, lost trabecular struts disconnect and cannot be rebuilt; recovery thickens surviving struts onto a permanently altered scaffold. Countermeasures: the bisphosphonate alendronate combined with the Advanced Resistive Exercise Device (ARED) suppresses resorption and largely prevents the loss; exercise alone partially offsets it but does not prevent trabecular loss.
Muscle. Trappe et al. (J Appl Physiol 2009, 6-month ISS, n=9) found calf volume dropped 13±2% (soleus –15%, gastrocnemius –10%), peak power fell ~32%, with a shift from slow to fast myosin fiber type. Lumbar paraspinal muscles atrophy 4.6–8.4% but generally recover within a year. Muscle recovers substantially faster than bone—mass mostly returns within months to a year—but full fiber-type and functional recovery can lag, and individual factors (age, sex) matter.
Neurological, cognitive, and ocular
Brain. Long-duration flight enlarges the brain's fluid-filled ventricles. Van Ombergen et al. (PNAS 2019, 11 cosmonauts, ~169 days) measured lateral ventricle +13.3%, third ventricle +10.4%, and total ventricular volume +11.6% post-flight; at 7-month follow-up these were still elevated (+7.7%, +4.7%, +6.4%), implying only partial (~40–55%) recovery. Roberts and colleagues documented ~11–25% total ventricular increases after ISS missions versus essentially zero after 2-week Shuttle flights. McGregor et al. (Scientific Reports 2023, n=30) found expansion occurs mostly in the first 6 months then tapers, and that crews with <3 years between missions show little additional enlargement because their ventricles haven't recovered compensatory capacity—suggesting a ~3-year recovery window.
SANS / vision. Mader et al. (Ophthalmology 2011) first characterized the syndrome: optic disc edema, globe flattening, choroidal folds, cotton-wool spots, and hyperopic refractive shifts. About 29% of short-duration and ~60% of long-duration crew report vision degradation, and optic disc edema is seen in up to ~70% of long-duration astronauts (Laurie et al., NASA). The leading mechanism is chronic headward fluid shift altering pressure at the back of the eye and around the optic nerve. Recovery is mixed: disc edema typically resolves over weeks to months, but globe flattening had only partially resolved one year after landing in a NASA MRI study, and choroidal folds and hyperopic shifts can persist for years (refractive shifts documented up to 10 years out). No permanent vision loss has been reported, but NASA regards SANS as a potential warning sign of more serious effects and a top risk for Mars missions.
Cognition. Group-level evidence is reassuring: a Frontiers (2024) study of ISS crew on 6-month missions found no widespread cognitive decline, only mild early slowing in processing speed/working memory. The Twins Study found Scott Kelly's in-flight cognition largely stable but a decrease in speed and accuracy after landing that persisted ~6 months. Some studies report "brain fog" and impaired dual-tasking. Psychological/isolation stressors are a parallel concern.
Brain. Long-duration flight enlarges the brain's fluid-filled ventricles. Van Ombergen et al. (PNAS 2019, 11 cosmonauts, ~169 days) measured lateral ventricle +13.3%, third ventricle +10.4%, and total ventricular volume +11.6% post-flight; at 7-month follow-up these were still elevated (+7.7%, +4.7%, +6.4%), implying only partial (~40–55%) recovery. Roberts and colleagues documented ~11–25% total ventricular increases after ISS missions versus essentially zero after 2-week Shuttle flights. McGregor et al. (Scientific Reports 2023, n=30) found expansion occurs mostly in the first 6 months then tapers, and that crews with <3 years between missions show little additional enlargement because their ventricles haven't recovered compensatory capacity—suggesting a ~3-year recovery window.
SANS / vision. Mader et al. (Ophthalmology 2011) first characterized the syndrome: optic disc edema, globe flattening, choroidal folds, cotton-wool spots, and hyperopic refractive shifts. About 29% of short-duration and ~60% of long-duration crew report vision degradation, and optic disc edema is seen in up to ~70% of long-duration astronauts (Laurie et al., NASA). The leading mechanism is chronic headward fluid shift altering pressure at the back of the eye and around the optic nerve. Recovery is mixed: disc edema typically resolves over weeks to months, but globe flattening had only partially resolved one year after landing in a NASA MRI study, and choroidal folds and hyperopic shifts can persist for years (refractive shifts documented up to 10 years out). No permanent vision loss has been reported, but NASA regards SANS as a potential warning sign of more serious effects and a top risk for Mars missions.
Cognition. Group-level evidence is reassuring: a Frontiers (2024) study of ISS crew on 6-month missions found no widespread cognitive decline, only mild early slowing in processing speed/working memory. The Twins Study found Scott Kelly's in-flight cognition largely stable but a decrease in speed and accuracy after landing that persisted ~6 months. Some studies report "brain fog" and impaired dual-tasking. Psychological/isolation stressors are a parallel concern.
Radiation and cancer risk
ISS sits within Earth's magnetosphere, so doses are far below deep-space levels but still ~10× terrestrial background. A 6-month mission delivers roughly 72 mSv (solar maximum) up to ~160 mSv (solar minimum); a 1-year mission near solar minimum is on the order of ~253 mSv (NASA LSAH). Scott Kelly's measured ~340-day mission gave 76.18 mSv physical (absorbed) dose and 146.34 mSv effective dose. NASA's standard limits career exposure to a 3% risk of exposure-induced death (REID); the National Academies (2021, "Space Radiation and Astronaut Health") recommended—and NASA adopted in 2022—a single career limit: "An individual astronaut's total career effective radiation dose due to spaceflight radiation exposure shall be less than 600 mSv. This limit is universal for all ages and sexes," based on the 3% REID for a 35-year-old female (the most radiosensitive reference subject). Radiation also raises risks of cataracts, cardiovascular disease, and central-nervous-system effects. A Mars round trip would exceed current limits, and a 2024 Nature Communications study (Siew et al., "Cosmic Kidney Disease") found that mice exposed to simulated 2.5-year galactic-cosmic-radiation doses suffered permanent kidney damage and loss of function—prompting the lead author's warning that Mars-returning astronauts "might need dialysis on the way back." That study also found spaceflight directly remodels the nephron (expanding the distal convoluted tubule while reducing overall tubule density) and alters salt handling, making kidney-stone risk a primary renal phenomenon and not merely a secondary consequence of bone loss.
ISS sits within Earth's magnetosphere, so doses are far below deep-space levels but still ~10× terrestrial background. A 6-month mission delivers roughly 72 mSv (solar maximum) up to ~160 mSv (solar minimum); a 1-year mission near solar minimum is on the order of ~253 mSv (NASA LSAH). Scott Kelly's measured ~340-day mission gave 76.18 mSv physical (absorbed) dose and 146.34 mSv effective dose. NASA's standard limits career exposure to a 3% risk of exposure-induced death (REID); the National Academies (2021, "Space Radiation and Astronaut Health") recommended—and NASA adopted in 2022—a single career limit: "An individual astronaut's total career effective radiation dose due to spaceflight radiation exposure shall be less than 600 mSv. This limit is universal for all ages and sexes," based on the 3% REID for a 35-year-old female (the most radiosensitive reference subject). Radiation also raises risks of cataracts, cardiovascular disease, and central-nervous-system effects. A Mars round trip would exceed current limits, and a 2024 Nature Communications study (Siew et al., "Cosmic Kidney Disease") found that mice exposed to simulated 2.5-year galactic-cosmic-radiation doses suffered permanent kidney damage and loss of function—prompting the lead author's warning that Mars-returning astronauts "might need dialysis on the way back." That study also found spaceflight directly remodels the nephron (expanding the distal convoluted tubule while reducing overall tubule density) and alters salt handling, making kidney-stone risk a primary renal phenomenon and not merely a secondary consequence of bone loss.
Immune system and latent viruses
Immune dysregulation persists for the full duration of 6-month flights: aspects of adaptive (T-cell) immunity are suppressed while some innate functions are heightened. Latent herpesvirus reactivation rises with mission length—in a study of 112 astronauts (Rooney, Crucian, Pierson, Laudenslager & Mehta, Frontiers in Microbiology 2019), VZV shedding increased from 41% (Shuttle) to 65% (ISS), EBV from 82% to 96%, and CMV from 47% to 61%. Up to ~50% of astronauts show some immunodeficiency on return, raising infection risk. A few reactivation cases have produced clinical disease (e.g., herpes zoster/shingles), and continued post-flight shedding poses a small transmission risk to immunocompromised contacts. The Twins Study confirmed Scott Kelly's immune system responded normally to an in-flight flu vaccine, a reassuring sign.
Immune dysregulation persists for the full duration of 6-month flights: aspects of adaptive (T-cell) immunity are suppressed while some innate functions are heightened. Latent herpesvirus reactivation rises with mission length—in a study of 112 astronauts (Rooney, Crucian, Pierson, Laudenslager & Mehta, Frontiers in Microbiology 2019), VZV shedding increased from 41% (Shuttle) to 65% (ISS), EBV from 82% to 96%, and CMV from 47% to 61%. Up to ~50% of astronauts show some immunodeficiency on return, raising infection risk. A few reactivation cases have produced clinical disease (e.g., herpes zoster/shingles), and continued post-flight shedding poses a small transmission risk to immunocompromised contacts. The Twins Study confirmed Scott Kelly's immune system responded normally to an in-flight flu vaccine, a reassuring sign.
Microbiome
Gut, skin, nasal, and oral microbial communities shift in flight—diversity changes, certain anti-inflammatory genera (e.g., Akkermansia) decline, and crewmates' microbiomes converge. Changes appear largely reversible, returning toward baseline within days to weeks of return; Scott Kelly's gut microbiome returned to its preflight state after landing. Whether in-flight dysbiosis itself harms health remains unproven.
Gut, skin, nasal, and oral microbial communities shift in flight—diversity changes, certain anti-inflammatory genera (e.g., Akkermansia) decline, and crewmates' microbiomes converge. Changes appear largely reversible, returning toward baseline within days to weeks of return; Scott Kelly's gut microbiome returned to its preflight state after landing. Whether in-flight dysbiosis itself harms health remains unproven.
Psychological effects
Isolation, confinement, circadian disruption, monotony, and separation from family create real risks of anxiety, depression, irritability, sleep disruption, and interpersonal conflict. At least one experienced astronaut became depressed during a long-duration mission. Communication delays will worsen this on Mars missions. Countermeasures include scheduled family contact, journaling, and psychological support.
Isolation, confinement, circadian disruption, monotony, and separation from family create real risks of anxiety, depression, irritability, sleep disruption, and interpersonal conflict. At least one experienced astronaut became depressed during a long-duration mission. Communication delays will worsen this on Mars missions. Countermeasures include scheduled family contact, journaling, and psychological support.
Long-duration (1-year+) findings: the Twins Study and beyond
The NASA Twins Study (Garrett-Bakelman et al., Science 2019, 364:eaau8650) remains the most comprehensive single dataset, comparing Scott Kelly (340 days) to his genetically identical Earth-bound brother Mark. Per lead investigator Christopher Mason, ~93% of Kelly's altered gene expression returned to normal once he was back on Earth, while a subset of several hundred "space genes" (immune, DNA repair, bone formation) remained disrupted; the paper notes "increased numbers of short telomeres were observed and expression of some genes was still disrupted" six months postflight. Telomeres unexpectedly lengthened in flight then shortened rapidly (mostly within ~48 hours of landing), leaving more critically short telomeres than baseline; chromosomal inversions persisted, indicating ongoing genomic instability; the carotid artery wall thickened early in flight and stayed thickened through the mission; body mass fell ~7%; and cognitive speed/accuracy decreased post-landing. The overall conclusion: human health can be "mostly sustained" for a year in space. Newer work—the 2024 SOMA package (44 papers, Nature and sub-journals, the largest-ever aerospace-medicine compendium, anchored on the Inspiration4 crew) and aging/frailty biomarker studies—frames spaceflight as a model of accelerated aging, with mitochondrial dysfunction, genomic instability, inflammation, and telomere/epigenetic changes mirroring terrestrial aging hallmarks. Frank Rubio's record 371-day single mission (returned September 2023) and the extended ~286-day mission of Butch Wilmore and Suni Williams (returned March 2025, with a 45-day reconditioning program) are still being studied, with no peer-reviewed individual health papers yet published.
The NASA Twins Study (Garrett-Bakelman et al., Science 2019, 364:eaau8650) remains the most comprehensive single dataset, comparing Scott Kelly (340 days) to his genetically identical Earth-bound brother Mark. Per lead investigator Christopher Mason, ~93% of Kelly's altered gene expression returned to normal once he was back on Earth, while a subset of several hundred "space genes" (immune, DNA repair, bone formation) remained disrupted; the paper notes "increased numbers of short telomeres were observed and expression of some genes was still disrupted" six months postflight. Telomeres unexpectedly lengthened in flight then shortened rapidly (mostly within ~48 hours of landing), leaving more critically short telomeres than baseline; chromosomal inversions persisted, indicating ongoing genomic instability; the carotid artery wall thickened early in flight and stayed thickened through the mission; body mass fell ~7%; and cognitive speed/accuracy decreased post-landing. The overall conclusion: human health can be "mostly sustained" for a year in space. Newer work—the 2024 SOMA package (44 papers, Nature and sub-journals, the largest-ever aerospace-medicine compendium, anchored on the Inspiration4 crew) and aging/frailty biomarker studies—frames spaceflight as a model of accelerated aging, with mitochondrial dysfunction, genomic instability, inflammation, and telomere/epigenetic changes mirroring terrestrial aging hallmarks. Frank Rubio's record 371-day single mission (returned September 2023) and the extended ~286-day mission of Butch Wilmore and Suni Williams (returned March 2025, with a 45-day reconditioning program) are still being studied, with no peer-reviewed individual health papers yet published.
Recommendations
For interpreting the science / decision-makers:
- Treat bone and ocular (SANS) findings as the binding constraints for long-duration human spaceflight—they are the effects most clearly shown to persist beyond a year. Mission planning, countermeasure R&D, and crew selection should prioritize these.
- Treat all deep-space (Mars/lunar) radiation, kidney, and combined-stressor projections as extrapolations from animal/analog/n=1 data, not established human outcomes. The single biggest evidence gap is the absence of human data beyond low-Earth orbit and beyond ~1 year.
Staged next steps for the field:
- Near term: Expand bone countermeasures (bisphosphonates + ARED, nutrition, possibly a single zoledronic-acid infusion), continue CIPHER-type multi-system monitoring on year-long ISS missions, and operationalize the 600 mSv radiation limit.
- Medium term: Develop and test artificial gravity, improved shielding, and SANS countermeasures (lower-body negative pressure, venoconstrictive thigh cuffs, pharmacology); recruit more female astronauts to resolve sex differences in bone/muscle loss and SANS susceptibility.
- Long term: Validate kidney/radiation protection and demonstrate a safe multi-year exposure profile before committing to crewed Mars transits.
Benchmarks that would change the assessment:
- If bone trabecular microstructure could be preserved (not just density), the skeletal risk reclassifies from "permanent" to "manageable."
- If a multi-year human (or high-fidelity animal) dataset shows kidney/CNS radiation effects are milder than the mouse models suggest, Mars-mission feasibility improves materially.
- If SANS is shown to progress to permanent vision loss in any astronaut, it becomes a hard limit requiring a solution before extended missions.
For interpreting the science / decision-makers:
- Treat bone and ocular (SANS) findings as the binding constraints for long-duration human spaceflight—they are the effects most clearly shown to persist beyond a year. Mission planning, countermeasure R&D, and crew selection should prioritize these.
- Treat all deep-space (Mars/lunar) radiation, kidney, and combined-stressor projections as extrapolations from animal/analog/n=1 data, not established human outcomes. The single biggest evidence gap is the absence of human data beyond low-Earth orbit and beyond ~1 year.
Staged next steps for the field:
- Near term: Expand bone countermeasures (bisphosphonates + ARED, nutrition, possibly a single zoledronic-acid infusion), continue CIPHER-type multi-system monitoring on year-long ISS missions, and operationalize the 600 mSv radiation limit.
- Medium term: Develop and test artificial gravity, improved shielding, and SANS countermeasures (lower-body negative pressure, venoconstrictive thigh cuffs, pharmacology); recruit more female astronauts to resolve sex differences in bone/muscle loss and SANS susceptibility.
- Long term: Validate kidney/radiation protection and demonstrate a safe multi-year exposure profile before committing to crewed Mars transits.
Benchmarks that would change the assessment:
- If bone trabecular microstructure could be preserved (not just density), the skeletal risk reclassifies from "permanent" to "manageable."
- If a multi-year human (or high-fidelity animal) dataset shows kidney/CNS radiation effects are milder than the mouse models suggest, Mars-mission feasibility improves materially.
- If SANS is shown to progress to permanent vision loss in any astronaut, it becomes a hard limit requiring a solution before extended missions.
Caveats
- Small samples. Most astronaut studies involve a handful to a few dozen subjects; the year-long human data is essentially n=1–2 (Kelly; Kelly + Kornienko). Statistical power is limited and individual variation is large.
- Conflicting figures. Orthostatic-intolerance incidence ranges from 30% (2026 pooled meta-analysis of 221 astronauts, duration-independent) to 83% (NASA Evidence Report, older long-duration data). The 6-month radiation dose varies roughly 2× with the solar cycle (~72–160 mSv). Report ranges, not single numbers.
- Animal/analog extrapolation. The dramatic kidney findings and some radiation effects come from mice and ground analogs (head-down bed rest, isolation chambers), not astronauts.
- Recent missions unpublished. Rubio (371 days) and Wilmore/Williams (286 days) health effects are so far described only via expert commentary in news media, not peer-reviewed papers.
- Sex imbalance. Most subjects are male; female-specific bone, muscle, and SANS responses are under-studied (women have lower baseline muscle/bone reserves, while the 600 mSv radiation standard is set by female radiosensitivity).
- Earth-shielding caveat. ISS findings understate deep-space risk because the ISS remains within Earth's protective magnetic field; lunar and Mars-transit radiation environments are substantially harsher.
- Small samples. Most astronaut studies involve a handful to a few dozen subjects; the year-long human data is essentially n=1–2 (Kelly; Kelly + Kornienko). Statistical power is limited and individual variation is large.
- Conflicting figures. Orthostatic-intolerance incidence ranges from 30% (2026 pooled meta-analysis of 221 astronauts, duration-independent) to 83% (NASA Evidence Report, older long-duration data). The 6-month radiation dose varies roughly 2× with the solar cycle (~72–160 mSv). Report ranges, not single numbers.
- Animal/analog extrapolation. The dramatic kidney findings and some radiation effects come from mice and ground analogs (head-down bed rest, isolation chambers), not astronauts.
- Recent missions unpublished. Rubio (371 days) and Wilmore/Williams (286 days) health effects are so far described only via expert commentary in news media, not peer-reviewed papers.
- Sex imbalance. Most subjects are male; female-specific bone, muscle, and SANS responses are under-studied (women have lower baseline muscle/bone reserves, while the 600 mSv radiation standard is set by female radiosensitivity).
- Earth-shielding caveat. ISS findings understate deep-space risk because the ISS remains within Earth's protective magnetic field; lunar and Mars-transit radiation environments are substantially harsher.
